Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-13

Clinical Trial Update: Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial update showing efficacy and safety of deucravacitinib versus placebo in adults with moderate-to-severe scalp psoriasis, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sotyktu (Deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2025-03-13